Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.
2.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
3.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
5.

Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V.

Antivir Ther. 2007;12(8):1247-54.

PMID:
18240864
6.

Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy.

Han SH, Chin BS, Choi HK, Shin SY, Chae YT, Baek JH, Kim CO, Choi JY, Song YG, Lee HC, Kim JM.

Tohoku J Exp Med. 2009 Oct;219(2):145-53.

7.

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9.

PMID:
11511820
8.

Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.

Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR.

J Int AIDS Soc. 2012 Jul 2;15(2):17427. doi: 10.7448/IAS.15.2.17427.

9.

Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART?

Chang KH, Kim JM, Song YG, Hong SK, Lee HC, Lim SK.

J Infect. 2002 Jan;44(1):33-8.

PMID:
11972416
10.

[Lipodystrophy and echographic hepatic steatosis in HIV-positive patients under highly active antiretroviral therapy (HAART) in Yaounde (Cameroon)].

Ongolo-Zogo P, Nkodo Mbia N, Mvogo Minkala TL, Biwole Sida M, Kouanfack C, Nko Amvene S.

Bull Soc Pathol Exot. 2012 Dec;105(5):353-60. doi: 10.1007/s13149-012-0253-x. Epub 2012 Aug 10. French.

PMID:
22886433
11.

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.

Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP.

AIDS. 2003 Jul 4;17(10):1503-11.

PMID:
12824788
12.

Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.

Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.

HIV Med. 2006 Jan;7(1):38-45.

13.

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy.

Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S.

Metabolism. 2002 Sep;51(9):1143-7.

PMID:
12200758
14.

A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine.

George JA, Venter WD, Van Deventer HE, Crowther NJ.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):771-81. doi: 10.1089/aid.2008.0308.

PMID:
19619010
15.

Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.

Bhutia E, Hemal A, Yadav TP, Ramesh KL.

Afr Health Sci. 2014 Jun;14(2):408-13. doi: 10.4314/ahs.v14i2.17.

16.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team.

Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.

17.
18.

Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.

Koppel K, Bratt G, Schulman S, Bylund H, Sandström E.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):441-9.

PMID:
11981359
19.

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.

Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H.

AIDS. 2002 Nov 8;16(16):2183-93.

PMID:
12409740
20.

Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

Worm D, Kirk O, Andersen O, Vinten J, Gerstoft J, Katzenstein TL, Nielsen H, Pedersen C.

HIV Med. 2002 Oct;3(4):239-46.

Supplemental Content

Support Center